BI-882370 is a specific RAF kinase inhibitor. BI-882370 inhibits the oncogenic BRAFV600E-mutant, the WT BRAF and CRAF kinases (IC50s: 0.4, 0.8 and 0.6 nM). BI-882370 also inhibits SRC family kinases.

B-Raf (V600E):0.4 nM, B-Raf:0.6 nM, C-Raf:0.8 nM

BI-882370 (0.9-6000 nM; 3 days) inhibits proliferation of BRAF-mutant human melanoma and colorectal cancer cells (EC50: 1-10 nM). BI 882370 (0.1-100 nM, 0.1-3000 nM; 2 hours) reduces p-MEK1/2, p-ERK1/2, and cyclin D1/D2 expression in BRAFV600E-mutant A375 cells and induces phosphorylation of MEK1/2 and enhances phosphorylation of ERK1/2 in WT BRO cells (3-300 nM). BI 882370 (0.1-100 nM, 0.1-3000 nM; 24 hours) suppresses cyclin D1/D2 expression and induces Kip1/p27 expression at concentrations of 1 nM or higher in BRAFV600E-mutant A375 cells, with no effect on expression of cyclins D1/D2 or Kip1/p27 in WT BRO cells.

BI-882370 (deliver orally; 25 mg/kg, 50 mg/kg; twice daily; 2 weeks) demonstrates efficacy in mouse models of BRAF-mutant melanomas and colorectal carcinomas, surpassing Vemurafenib, Dabrafenib, or Trametinib. BI-882370 (p.o; 25 mg/kg; twice daily; 40 days) develops resistance within 3 weeks, but no resistance is observed during a 5-week second-line therapy with trametinib. BI-882370 (deliver orally; 60 mg/kg; once daily; 2 weeks) exhibits no toxicity in clinical chemistry, hematology, pathology, and toxicogenomics in rats.

Cell Line: BRAF-mutant and WT melanoma cell lines (A101D, A375, SK-MEL-28, G-361, and BRO); Colorectal cancer cell lines (COLO 205, HT-29, LS411N, and HCT-116). Concentration: 0.9-6000 nM. Incubation Time: 3 days

Animal Model: Human melanoma xenografts in nude mice with BRAF-mutant melanomas and colorectal carcinomas cells (A375, COLO 205; G-361, HT-29 cells). Dosage: 25 mg/kg; 50 mg/kg. Administration: Deliver orally; 25 mg/kg, 50 mg/kg; twice daily; 2 weeks